CLL BTK Inhibitor Tx and AE Guide

CME

Global Perspectives and Clinical Resources to Guide Treatment Decisions and Management of Adverse Events With BTK Inhibitor Therapy in CLL 

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 13, 2025

Expiration: September 12, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this module, Stephan Stilgenbauer, MD, discusses the clinical evidence and global perspectives on the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with BTK inhibitors and the management of adverse events (AEs) in patients with CLL.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. 

Please note that Clinical Care Options plans to measure the educational impact of this activity. Some questions are asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with CLL/SLL do you provide care for in a typical month?

Currently, which of the following BTK inhibitors has/have an approved indication in combination with venetoclax?

Ms Johnson is a 68-year-old woman with newly diagnosed CLL and del(17p) detected on her workup. She has been experiencing fatigue and frequent infections. She has a history of arterial hypertension.

Which of the following initial treatment options is best suited for Ms Johnson?

Approximately 6 months after starting treatment with acalabrutinib 100 mg orally twice daily, Ms Johnson develops grade 1 atrial fibrillation. Which of the following would be the most appropriate next step to manage this AE?